# Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

> **NCT05462613** · PHASE2,PHASE3 · RECRUITING · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 446 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **OTHER:** quality of life questionnaires
- **PROCEDURE:** Blood sample
- **DRUG:** Regorafenib
- **DRUG:** Metronomic chemotherapies
- **DRUG:** Aspirin
- **DRUG:** Bevacizumab
- **DRUG:** FOLFIRI or FOLFOX

## Key facts

- **NCT ID:** NCT05462613
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-09
- **Primary completion:** 2029-11
- **Final completion:** 2030-11
- **Target enrollment:** 446 (ESTIMATED)
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05462613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05462613, "Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05462613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*